Immunoadsorption in Dermatology
Article first published online: 15 MAY 2012
© 2012 The Authors. Therapeutic Apheresis and Dialysis © 2012 International Society for Apheresis
Therapeutic Apheresis and Dialysis
Volume 16, Issue 4, pages 311–320, August 2012
How to Cite
Meyersburg, D., Schmidt, E., Kasperkiewicz, M. and Zillikens, D. (2012), Immunoadsorption in Dermatology. Therapeutic Apheresis and Dialysis, 16: 311–320. doi: 10.1111/j.1744-9987.2012.01075.x
- Issue published online: 22 JUL 2012
- Article first published online: 15 MAY 2012
- Received March 2012.
- Atopic dermatitis;
Immunoadsorption (IA) has been successfully used in a large variety of autoantibody-mediated disorders. In dermatology, IA is increasingly applied as adjuvant treatment for severe and/or refractory autoimmune bullous diseases. These disorders are characterized by autoantibodies against structural proteins of the skin and/or mucous membranes and include, among others, pemphigus vulgaris, pemphigus foliaceus, and bullous pemphigoid. Autoimmune blistering diseases are associated with a high mortality (pemphigus) or morbidity (bullous pemphigoid) and in particular in pemphigus diseases, treatment is challenging. The pathogenetic role of autoantibodies in most of the immunobullous diseases has been clearly demonstrated, therefore, removal of these autoantibodies is a rational therapeutic approach. IA has been shown to effectively lower the serum autoantibodies and to lead to rapid clinical responses. Most recently, IA has been successfully applied in patients with severe atopic dermatitis and high total serum IgE levels. Here, the different treatment protocols, clinical efficacy, and adverse events are summarized.